- Home
- PHT vs YMAB Comparison
PHT vs YMAB Comparison
Compare PHT & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHT
- YMAB
- Stock Information
- Founded
- PHT 2002
- YMAB 2015
- Country
- PHT United States
- YMAB United States
- Employees
- PHT N/A
- YMAB N/A
- Industry
- PHT Investment Managers
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- PHT Finance
- YMAB Health Care
- Exchange
- PHT Nasdaq
- YMAB Nasdaq
- Market Cap
- PHT 232.7M
- YMAB 270.5M
- IPO Year
- PHT N/A
- YMAB 2018
- Fundamental
- Price
- PHT $7.88
- YMAB $5.72
- Analyst Decision
- PHT
- YMAB Strong Buy
- Analyst Count
- PHT 0
- YMAB 10
- Target Price
- PHT N/A
- YMAB $21.10
- AVG Volume (30 Days)
- PHT 85.5K
- YMAB 542.6K
- Earning Date
- PHT 01-01-0001
- YMAB 03-04-2025
- Dividend Yield
- PHT 8.76%
- YMAB N/A
- EPS Growth
- PHT N/A
- YMAB N/A
- EPS
- PHT 0.98
- YMAB N/A
- Revenue
- PHT N/A
- YMAB $84,553,000.00
- Revenue This Year
- PHT N/A
- YMAB $6.41
- Revenue Next Year
- PHT N/A
- YMAB $18.15
- P/E Ratio
- PHT $7.71
- YMAB N/A
- Revenue Growth
- PHT N/A
- YMAB N/A
- 52 Week Low
- PHT $6.41
- YMAB $5.60
- 52 Week High
- PHT $7.60
- YMAB $20.90
- Technical
- Relative Strength Index (RSI)
- PHT 48.90
- YMAB 35.08
- Support Level
- PHT $7.85
- YMAB $5.60
- Resistance Level
- PHT $7.96
- YMAB $6.57
- Average True Range (ATR)
- PHT 0.07
- YMAB 0.38
- MACD
- PHT -0.01
- YMAB 0.10
- Stochastic Oscillator
- PHT 21.43
- YMAB 11.43
About PHT Pioneer High Income Fund Inc.
Pioneer High Income Trust is a closed-end management investment company. Its investment objective is to provide a high level of current income and to seek capital appreciation by investing predominantly in below investment grade (high-yield) debt securities, loans, and preferred stocks.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.